These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15298958)

  • 1. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica.
    Wang SS; Trunk M; Schiffman M; Herrero R; Sherman ME; Burk RD; Hildesheim A; Bratti MC; Wright T; Rodriguez AC; Chen S; Reichert A; von Knebel Doeberitz C; Ridder R; von Knebel Doeberitz M
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1355-60. PubMed ID: 15298958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic markers of high-grade squamous intraepithelial lesions: the role of p16INK4a and high-risk human papillomavirus.
    Eleutério J; Giraldo PC; Gonçalves AK; Cavalcante DI; de Almeida Ferreira FV; Mesquita SM; Morais SS
    Acta Obstet Gynecol Scand; 2007; 86(1):94-8. PubMed ID: 17230296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear.
    Monsonego J; Pollini G; Evrard MJ; Sednaoui P; Monfort L; Quinzat D; Dachez R; Syrjänen K
    Int J STD AIDS; 2008 Jun; 19(6):385-92. PubMed ID: 18595876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating Diagnostic Problems of CIN1 and CIN2 Associated With High-risk HPV by Combining the Novel Molecular Biomarker PanHPVE4 With P16INK4a.
    van Baars R; Griffin H; Wu Z; Soneji YJ; van de Sandt M; Arora R; van der Marel J; Ter Harmsel B; Jach R; Okon K; Huras H; Jenkins D; Quint W; Doorbar J
    Am J Surg Pathol; 2015 Nov; 39(11):1518-1528. PubMed ID: 26379150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
    Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
    Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16 Immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing.
    Zhang G; Yang B; Abdul-Karim FW
    Int J Gynecol Pathol; 2015 Mar; 34(2):180-6. PubMed ID: 25675189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project.
    Herrero R; Schiffman MH; Bratti C; Hildesheim A; Balmaceda I; Sherman ME; Greenberg M; Cárdenas F; Gómez V; Helgesen K; Morales J; Hutchinson M; Mango L; Alfaro M; Potischman NW; Wacholder S; Swanson C; Brinton LA
    Rev Panam Salud Publica; 1997 May; 1(5):362-75. PubMed ID: 9180057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
    Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
    J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNIPER: a novel assay for human papillomavirus testing among women in Guizhou, China.
    Belinson SE; Wulan N; Li R; Zhang W; Rong X; Zhu Y; Wu R; Belinson JL
    Int J Gynecol Cancer; 2010 Aug; 20(6):1006-10. PubMed ID: 20683409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment.
    Stanczuk GA; Currie H; Baxter G; Foster A; Gibson L; Graham C; Cuschieri K
    J Clin Pathol; 2015 Jul; 68(7):567-70. PubMed ID: 25878328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
    Sand FL; Munk C; Frederiksen K; Junge J; Iftner T; Dehlendorff C; Kjaer SK
    Int J Cancer; 2019 Apr; 144(8):1975-1982. PubMed ID: 30246864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China.
    Liao GD; Sellors JW; Sun HK; Zhang X; Bao YP; Jeronimo J; Chen W; Zhao FH; Song Y; Cao Z; Zhang SK; Xi MR; Qiao YL
    Int J Cancer; 2014 Apr; 134(7):1715-24. PubMed ID: 24105727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
    Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
    Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular progression to cervical precancer, epigenetic switch or sequential model?
    Nedjai B; Reuter C; Ahmad A; Banwait R; Warman R; Carton J; Boer S; Cuzick J; Lorincz AT
    Int J Cancer; 2018 Oct; 143(7):1720-1730. PubMed ID: 29679470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples.
    Nasioutziki M; Daniilidis A; Dinas K; Kyrgiou M; Valasoulis G; Loufopoulos PD; Paraskevaidis E; Loufopoulos A; Karakitsos P
    Int J Gynecol Cancer; 2011 Jan; 21(1):79-85. PubMed ID: 21330832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
    Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.